Edition:
United Kingdom

Aquinox Pharmaceuticals Inc (AQXP.OQ)

AQXP.OQ on NASDAQ Stock Exchange Global Market

12.74USD
23 May 2018
Change (% chg)

$0.37 (+2.99%)
Prev Close
$12.37
Open
$12.33
Day's High
$12.87
Day's Low
$12.27
Volume
21,870
Avg. Vol
31,236
52-wk High
$16.85
52-wk Low
$10.03

Latest Key Developments (Source: Significant Developments)

Aquinox Pharmaceuticals qtrly ‍net loss per share $0.50​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Aquinox Pharmaceuticals Inc -:Aquinox Pharmaceuticals announces third quarter 2017 financial results.Aquinox Pharma - ‍continues to expect that its cash-on-hand will carry it beyond top-line data from leadership 301 trial and at least to mid-2019.Aquinox Pharmaceuticals Inc - qtrly ‍net loss per common stock $0.50​.Aquinox Pharmaceuticals - ‍cash, cash equivalents, short-term, long-term investments totaled $119.7 million as of Sept 30 versus 153.1 million as of Dec 31, 2016​.  Full Article

T. Rowe Price Associates Inc reports 14.4 pct passive stake in Aquinox Pharmaceuticals
Tuesday, 11 Oct 2016 

T. Rowe Price Associates Inc:T. Rowe Price Associates Inc reports 14.4 percent passive stake in Aquinox Pharmaceuticals Inc as of sept. 30 - SEC filing.  Full Article

Aquinox Pharmaceuticals Inc - qtrly loss per share $0.63
Thursday, 4 Aug 2016 

Aquinox Pharmaceuticals Inc : Aquinox Pharmaceuticals announces second quarter 2016 financial results . Qtrly loss per share $0.63 .Q2 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF- Astellas Pharma signs exclusive licensing agreement with Aquinox Pharmaceuticals

* Says it signed an exclusive license agreement with Aquinox Pharmaceuticals, Inc for Japan and certain other countries in the Asia-Pacific region for Astellas to develop and commercialize rosiptor, Aquinox’s lead drug candidate, a first-in-class, once-daily oral treatment currently in Phase 3 clinical development for interstitial cystitis/bladder pain syndrome (IC/BPS) in North America and Europe